Ifosfamide: profile and news

NCCN Announces Important Updates to Ovarian Cancer Clinical ...  07 Mar 2006
...for ovarian cancer to include anastrazole (Arimidex, AstraZeneca), bevacizumab (Avastin, Genentech), irinotecan (Camptosar, Pfizer), ifosfamide (Ifex, Bristol ... - Genetic Engineering News,

ZIOPHARM Presents ZIO-201 Preclinical Kidney Toxicity Data at Bone ...  Feb 21, 2006
ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) presented preclinical data showing ZIO-201, the active metabolite of ifosfamide, may be less likely to kill normal ... - Genetic Engineering News,

ZIOPHARM Treats First Patient in ZIO-201 Phase I/II in Sarcoma ...  Feb 23, 2006
ZIO-201 (isophosphoramide mustard or IPM) is the active metabolite of ifosfamide, a frequently used treatment for sarcoma. Due to ... - Genetic Engineering News,

ZIOPHARM Presents ZIO-201 Preclinical Kidney Toxicity Data at Bone ...  Feb 21, 2006
...(OTC BB: ZIOP) presented preclinical data showing ZIO-201, the active metabolite of ifosfamide, may be less likely to kill normal kidney cells than the other ... - PharmaLive.com (press release),

Ziopharm initiates trial of sarcoma drug  Feb 24, 2006
ZIO-201 is the active metabolite of ifosfamide, a frequently used, yet highly toxic, treatment for sarcoma. ZIO-201 is designed ... - Pharmaceutical Business Review

Neoadjuvant Sarcoma Chemotherapy Results in High Toxicity Levels  Mar 1, 2006
The patients received three cycles of neoadjuvant modified mesna, doxorubicin, ifosfamide and dacarbazine (MAID), interdigitated radiotherapy and following ... - Cancerpage.com,

Ziopharm compound shows potential for bone marrow transplants  Feb 21, 2006
Hawaii. Alkylators like cyclophosphamide and ifosfamide are widely used to prepare people for blood cell and bone marrow transplant. ... - Pharmaceutical Business Review

Neoadjuvant Chemotherapy and Radiotherapy Promising for Large Soft ...  Mar 3, 2006
All were scheduled to receive neoadjuvant concomitant radiotherapy and chemotherapy with MAID (mesna, ifosfamide, doxorubicin and dacarbazine). ... - Cancer Consultants (press release),

ZIOPHARM Presents ZIO-201 Preclinical Data at Bone Marrow ...  Feb 17, 2006
...colleagues. Alkylators like cyclophosphamide and ifosfamide are widely used to prepare people for blood cell and bone marrow transplant. ... - Genetic Engineering News,

ARIAD Initiates First Clinical Trial of Oral AP23573 in ...  Feb 14, 2006
The alkylating agent, ifosfamide, is often used in conjunction with doxorubicin in this clinical setting. Once the tolerability ... - Genetic Engineering News,

FDA Approves EMEND(R) (aprepitant), in Combination with Other ...  Jan 11, 2006
Chemotherapy agents that are known to be metabolized by CYP3A4 include docetaxel, paclitaxel, etoposide, irinotecan, ifosfamide, imatinib, vinorelbine ... - Business Wire (press release),

Novel Strategies for Treating Lung Cancer: Chemotherapy  Jan 24, 2006
...mitomycin, vindesine, cisplatin) and BLT (Big Lung Trial from Great Britain) [9] using cisplatin combined with either vindesine, mitomycin, ifosfamide, or with ... - Medscape (subscription)

Cisplatin Benefits Patients with Metastatic Osteosarcoma  Jan 12, 2006
...treatment). The first trial assessed the chemotherapy drugs ifosfamide, cisplatin, doxorubicin, and high-dose methotrexate. The ... - Cancer Consultants (press release),

ZIOPHARM Oncology Announces ZIO-201 ASH Abstract Publication  Nov 21, 2005
In abstract 4727 titled "Isophosphoramide Mustard-lysine (ZIO-201): Active Moiety of Ifosfamide (IFOS) without Kidney Toxicity," by Mary Taub and coworkers at ... - Business Wire (press release),

Survival rate still poor when bone cancer returns  Dec 2, 2005
..."The probability for long-term disease-free survival," he added, "may be enhanced by the use of high-dose ifosfamide" after surgery. ... - Reuters.uk,

Despite Poor Prognosis, New Treatment Options for Mesothelioma May ...  Nov 15, 2005
A trial of combined ifosfamide and interferon-alpha2a, which extended survival to 21 months for some patients who tolerated a 3-dose schedule. ... - DG News

Ifosfamide/Paclitaxel/Cisplatin Highly Effective for Recurrent ...  Sep 22, 2005
According to results recently published in the Journal of Clinical Oncology, the chemotherapy combination of ifosfamide (Ifex®), paclitaxel (Taxol®), and ... - Cancer Consultants (press release),

Taxol®, Ifex® and Platinol® Effective Second-Line Therapy for ...  Sep 22, 2005
...with testicular cancer relapsing after an initial remission became long-term survivors after treatment with Taxol (paclitaxel), Ifex (ifosfamide) and Platinol ... - Cancer Consultants (press release),

ZIOPHARM, Inc. and EasyWeb, Inc. Merge to Form ZIOPHARM Oncology ...  Sep 15, 2005
ZIO-201, subject of US and international patent applications, is a proprietary formulation of isophosphoramide mustard, the active metabolite of ifosfamide. ... - Business Wire (press release),

Chemotherapy and Stem Cells Combat Osteosarcoma  Sep 20, 2005
They received two cycles of induction chemotherapy with cisplatin, doxorubicin, and ifosfamide, followed by high-dose chemotherapy. ... - Cancerpage.com,

Tandem High-dose Treatments Better than Single High-dose Treatment ...  Aug 2, 2005
Transplant regimens included Novantrone® (mitoxantrone) and Thioplex® or IFEX® (ifosfamide), Paraplatin® (carboplatin) and etoposide (ICE). ... - Cancer Consultants (press release)

New Regimen Effective for Relapsed Non-Hodgkin’s Lymphoma  Jul 18, 2005
Researchers from Italy have developed a new treatment regimen consisting of lomustine, ifosfamide, bleomycin, vincristine and cisplatin (CIBO-P) that produces ... - Cancer Consultants (press release)

Palliative Pain Management: When Both Pain and Suffering Hurt  Jul 15, 2005
A man in his 20s, with relapsed osteosarcoma progressing rapidly in his bones and lungs, was on hemodialysis for ifosfamide-induced end-stage renal failure ... - RedNova.com

New Regimen Effective For Refractory non-Hodgkin's Lymphoma  Jun 3, 2005
..."CIBO-P (lomustine, ifosfamide, bleomycin, vincristine, and cisplatin) is a novel salvage regimen for patients with aggressive NHL," Dr. Antonino Musolino from ... - Cancerpage.com,

ZIOPHARM Presents ZIO-201 Preclinical Data at AACR; Phase I ...  Apr 19, 2005
Anaheim, California. ZIO-201 is the Company's proprietary alkylating drug and the active metabolite of ifosfamide. Pharmaceutical ... - Genetic Engineering News

News For Your Web Site  Apr 19, 2005
Chemotherapy agents that are known to be metabolized by CYP3A4 include docetaxel, paclitaxel, etoposide, irinotecan, ifosfamide, imatinib, vinorelbine ... - dBusinessNews Newark

ZIOPHARM Announces Approval of IND for ZIO-101; Phase I Trial in ...  Apr 5, 2005
Thornton continued, "With respect to our other compound in clinical development, ZIO-201, the small molecule stable active metabolite of ifosfamide, our Phase ... - Business Wire

Baxa Sponsors Exhibitor’s Theatre on Reducing Environmental  Apr 6, 2005
The presentation details the findings from a study on biological uptake of cyclophosphamide and ifosfamide in the infusion center pharmacy and nursing staff at ... - Khalsa News Network,

Powerful drugs endanger unprotected health workers  Mar 10, 2005
Blood and urine samples from pharmacists, nurses and technicians were to be analyzed for the presence of chemotherapy drugs like cytoxan and ifosfamide. ... - People's Weekly World

Brain tumor with dismal prognosis in infants can be cured in older ...  Mar 2, 2005
The study also demonstrated that older children who experienced relapse of ATRT could be saved using ICE chemotherapy (ifosfamide, carboplatin- and etoposide). ... - Medical News Today,

What if the Cure is Also a Cause?  Feb 14, 2005
...and look for signs of drugs such as cyclophosphamide (usually administered intravenously to treat lymphoma, leukemia or breast cancer) and ifosfamide (also an ... - Washington Post

The physician should be alert for possible combined drug actions, desirable or undesirable, involving ifosfamide even though ifosfamide has been used successfully concurrently with other drugs, including other cytotoxic drugs.